Based on results from a phase 3 clinical trial, TAP Pharmaceutical Products Inc., the makers of febuxostat, have submitted an application seeking FDA approval for febuxostat in the management of hyperuricemia in patients with chronic gout. Results from a Phase 3 clinical trial showed that daily oral febuxostat (80 or 120 mg) is effective in reducing the level of serum uric acid in subjects with gout and hyperuricemia compared to allopurinol 300 mg per day. Safety of both doses of febuxostat was comparable to allopurinol, currently the only approved treatment for gout.
Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.
Use of this Site
All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.